Insilico Medicine and SK Biopharmaceuticals have announced a collaboration at the BIO 2026 International Convention to develop AI-driven drug candidates for neuroimmune disorders affecting the central nervous system (CNS). This partnership combines Insilico’s proprietary Pharma.AI platform with SK’s clinical development expertise, aiming to accelerate drug discovery and improve treatment outcomes in a challenging therapeutic area with significant unmet needs. The deal could yield over $2.5 billion in total value, marking a significant milestone for Insilico in its collaborations within Asia-Pacific. Both companies emphasize the scalable potential of this partnership to address critical patient needs in CNS therapy development.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://insilico.com/news/zm8me18st1-insilico-medicine-and-sk-biopharmaceutic
